title: Reimplantation valve-sparing aortic root replacement in Marfan syndrome using the Valsalva conduit: an intercontinental multicenter study.
abstract: BACKGROUND
  Introduced by DePaulis in 2000, the Gelweave Valsalva graft (Sulzer Vascutek, Refrewshire, Scotland) is a modified Dacron conduit (DuPont, Wilmington, DE), with prefashioned sinuses of Valsalva. The aim of this study was to evaluate the mid-term results of the reimplantation valve-sparing aortic root replacement using the Gelweave Valsalva prosthesis in Marfan syndrome patients.
  
  
  METHODS
  A retrospective review was performed of 35 patients with Marfan syndrome in four centers who underwent the reimplantation valve-sparing aortic root replacement using the Gelweave Valsalva prosthesis.
  
  
  RESULTS
  The patients were predominantly men, with a mean age of 36.5 +/- 12.6 years (range, 14 to 62 years). Two patients presented with acute type A dissections and underwent emergent operations. Elective hemiarch reconstruction using hypothermic circulatory arrest was required in 11 patients. Aortic valve cusp repair was performed in 2 patients. There were no operative or hospital deaths, and no patients died during follow-up. The mean follow-up was 19 months (range, 1 to 60 months). Significant (>2+) aortic insufficiency (AI), requiring aortic valve replacement, developed in 3 patients during follow-up that requiring aortic valve replacement. The 5-year freedom from reoperation owing to structural valve deterioration was 88.9% +/- 8.1%. There were no episodes of clinically significant thromboembolism.
  
  
  CONCLUSIONS
  Reimplantation valve-sparing aortic root replacement with the Gelweave Valsalva prosthesis in Marfan patients provides satisfactory mid-term results, thus encouraging further use of this type of repair. However, long-term results are needed in order to define the durability of this technique.
authors.affiliation: Cardiac Surgery Department, Istituto Clinico Humanitas, Rozzano, Italy. fabrizio.settepani@humanitas.it
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Settepani
authors.forename: Wilson Y
authors.initials: WY
authors.lastname: Szeto
authors.forename: Davide
authors.initials: D
authors.lastname: Pacini
authors.forename: Ruggero
authors.initials: R
authors.lastname: De Paulis
authors.forename: Luigi
authors.initials: L
authors.lastname: Chiariello
authors.forename: Roberto
authors.initials: R
authors.lastname: Di Bartolomeo
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallotti
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Bavaria
mesh_terms: D000293:Adolescent; D000328:Adult; D001011:Aorta / Q000601:surgery*; D001018:Aortic Diseases / Q000209:etiology* / Q000601:surgery*; D001021:Aortic Valve / Q000503:physiopathology / Q000601:surgery*; D001022:Aortic Valve Insufficiency / Q000209:etiology / Q000601:surgery; D019917:Blood Vessel Prosthesis Implantation; D005260:Female; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008382:Marfan Syndrome / Q000150:complications*; D008875:Middle Aged; D012086:Reoperation; D012092:Replantation / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome